The trading price of Standard BioTools Inc (NASDAQ:LAB) closed lower on Monday, March 03, and closing at $1.01, -5.16% lower than its previous close.
In examining the 52-week price action we see that the stock hit a 52-week high of $3.04 and a 52-week low of $1.00. Over the past month, the stock has lost -37.27% in value.
Standard BioTools Inc, whose market valuation is $375.99 million at the time of this writing, is expected to release its quarterly earnings report in April. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by -0.04 per share this quarter, however they have predicted annual earnings per share of -0.16 for current year and -0.09 for next year.
Analysts have forecast the company to bring in revenue of 40.1M for the current quarter, with the likely lows of 39.3M and highs of 40.8M. From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue is 169.2M.
On the technical side, indicators suggest LAB has a 100% Sell on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 100% Sell, while an average of long term indicators suggests that the stock is currently 100% Sell.
Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned LAB a recommendation rating is 3. Out of them, 0 rate it a Hold, while 3 recommend Buy, whereas 0 assign an Overweight rating. 0 analyst(s) have tagged Standard BioTools Inc (LAB) as Underweight, while 0 advise Sell. Analysts have rated the stock Buy, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.
A quick review shows that LAB’s price is currently -23.11% off the SMA20 and -37.22% off the SMA50. The RSI metric on the 14-day chart is currently showing 26.25, and weekly volatility stands at 12.00%. When measured over the past 30 days, the indicator reaches 8.48%. Standard BioTools Inc (NASDAQ:LAB)’s beta value is currently sitting at 1.62, while the Average True Range indicator is currently displaying 0.12. With analysts defining $3.25-$3.25 as the low and high price targets, we arrive at a consensus price target of $3.25 for the trailing 12-month period. The current price is about -221.78% off the estimated low and -221.78% off the forecast high, based on this estimate. Investors will be thrilled if LAB’s share price rises to $3.25, which is the median consensus price. At that level, LAB’s share price would be -221.78% below current price.
To see how Standard BioTools Inc stock has been performing in comparison to its peers in the industry, here are the numbers: LAB stock’s performance was -5.16% in the latest trading, and -57.38% in the past year, while Thermo Fisher Scientific Inc. (TMO) has traded -1.01%% on the day and positioned -9.97% lower than it was a year ago. Another comparable company Pacific Biosciences of California Inc. (PACB) saw its stock close -9.31%% lower in the most recent trading session but was down -73.05% in a year.
An evaluation of the daily trading volume of Standard BioTools Inc (NASDAQ:LAB) indicates that the 3-month average is 1.84 million.
Currently, records show that 372.26 million of the company’s shares remain outstanding. The insiders hold 3.16% of outstanding shares, whereas institutions hold 72.48%. However, since the stock’s price has seen -42.29% year-to-date, investors’ interest is likely to be reignited due to its potential to move even lower.
